Danesino Cesare, Cantarini Claudia, Olivieri Carla
General Biology and Medical Genetics Unit, Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
Pediatr Rep. 2023 Feb 10;15(1):129-142. doi: 10.3390/pediatric15010011.
Hereditary Hemorrhagic Telangiectasia (HHT) or Rendu-Osler-Weber Syndrome (ROW) is an autosomal dominant vascular disease, with an estimated prevalence of 1:5000. Genes associated with HHT are , , , and , all encoding for proteins involved in the TGFβ/BMPs signaling pathway. The clinical diagnosis of HHT is made according to the "Curaçao Criteria," based on the main features of the disease: recurrent and spontaneous epistaxis, muco-cutaneous telangiectases, arteriovenous malformations in the lungs, liver, and brain, and familiarity. Since the clinical signs of HHT can be misinterpreted, and the primary symptom of HHT, epistaxis, is common in the general population, the disease is underdiagnosed. Although HHT exhibits a complete penetrance after the age of 40, young subjects may also present symptoms of the disease and are at risk of severe complications. Here we review the literature reporting data from clinical, diagnostic, and molecular studies on the HHT pediatric population.
遗传性出血性毛细血管扩张症(HHT)或朗杜-奥斯勒-韦伯综合征(ROW)是一种常染色体显性血管疾病,估计患病率为1:5000。与HHT相关的基因有、、和,所有这些基因都编码参与转化生长因子β/骨形态发生蛋白(TGFβ/BMPs)信号通路的蛋白质。HHT的临床诊断依据“库拉索标准”,基于该疾病的主要特征:反复自发性鼻出血、黏膜皮肤毛细血管扩张、肺、肝和脑的动静脉畸形以及家族史。由于HHT的临床体征可能被误解,且HHT的主要症状鼻出血在普通人群中很常见,因此该疾病诊断不足。尽管HHT在40岁以后表现出完全显性,但年轻患者也可能出现该疾病的症状,并面临严重并发症的风险。在此,我们回顾了有关HHT儿科人群临床、诊断和分子研究报告数据的文献。